Decatecholaminization - what’s new?




Prof. Dr. med. Matthias Heringlake
Prim. Doz. Dr. Johann Knotzer, MSc

Learning Targets

  • mortality from septic shock is still inaccetably high
  • conventional approaches for optimizing hemodynamics have been associated with adverse outcomes
  • the use of betamimetic drugs leads to an increased production of proinflammatory cytokines
  • treatment with betablocking agents and vasopressin may counteract the inflammatory response observed during severe cardiocirculatory stress and septic shock
  • the use of vasopressin in septic shock is associated with reduced mortality in patients with less severe shock and improved renla function in patients with already compromised renal function.
  • treatment with the short acting betablocker esmolol improves outcomes from septic shock
  • the new short-acting betablocker landiolol has less negative inotropic and blood pressure lowering effects than esmolol
  • the current evidence on using levosimendan in patients with septic shock does not rule out a beneficial effect in patients with confirmed septic cardiomyopathy


Lecture Board

Assoz.-Prof. Dr. Axel Kleinsasser
Prim. Univ.-Prof. Dr. Alexander Löckinger

Accreditation Information

The e-learning activity “Decatecholaminization - what’s new?” is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The e-learning activity is awarded with 1 European CME credits (ECMEC’s).

course type image
valid until 25.09.2021